Risk factors in pediatric stem cell transplantation for leukemia

Pediatric Transplantation
Asa Gustafsson JernbergJ Winiarski

Abstract

To investigate which factors impact on survival, relapse, relapse free survival, transplant-related mortality (TRM) and graft-versus-host disease (GVHD) in children who undergo allogeneic stem cell transplantation, we included all 181 children transplanted due to leukemia at our unit. At the end of follow up 54% of the patients were alive, 27% had died due to relapse while 19% had died of other causes. Survival was similar in recipients of related (55%) and unrelated grafts (48%). Risk factors identified in univariate analysis were brought into a multivariable analysis. However, an unrelated donor was not identified as a risk factor for any of the five end-points analysed. A donor positive for three to four herpes viruses increased the risk of acute GVHD, TRM and death. A female to male transplant increased the risk of TRM, particularly if combined with a mismatch. Early stage of disease as well as human leukocyte antigen (HLA)-matching independently predicted survival. The risk of relapse increased after 1992. Chronic GVHD independently decreased the risk of relapse (relative risk RR, 0.39) and death (RR 0.42). We conclude that in children with leukemia other specific donor characteristics such as HLA-matching, gender, parity,...Continue Reading

References

May 10, 1979·The New England Journal of Medicine·P L WeidenR Storb
Oct 1, 1988·Transplantation·L BoströmB Nilsson
Dec 1, 1987·British Journal of Haematology·R P GaleJ H Kersey
Aug 1, 1980·The American Journal of Medicine·H M ShulmanE D Thomas
Nov 9, 1995·The New England Journal of Medicine·P J Landrigan
Jun 15, 1995·The New England Journal of Medicine·C H Pui
Oct 28, 1993·The New England Journal of Medicine·G K RiveraW M Crist
Mar 4, 1993·The New England Journal of Medicine·N A KernanJ McCullough
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M DaviesN K Ramsay
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R SzydloM M Horowitz
Oct 6, 1999·Current Opinion in Immunology·E W PetersdorfJ A Hansen
Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U M Saarinen-PihkalaUNKNOWN Nordic Society of Pediatric Hematology and Oncology
Nov 10, 2001·Hematology·Malcolm BrennerEls Goulmy
Feb 19, 2002·British Journal of Haematology·Franklin O SmithUNKNOWN National Marrow Donor Program
Apr 20, 2002·Blood·Nancy BuninUNKNOWN National Marrow Donor Program Working Group
Mar 7, 2003·Bone Marrow Transplantation·A Gustafsson JernbergJ Winiarski

❮ Previous
Next ❯

Citations

Jul 19, 2008·Anesthesia and Analgesia·Marie Csete
Jan 18, 2011·Hematology/oncology Clinics of North America·Per LjungmanMichael Boeckh
May 15, 2010·Infectious Disease Clinics of North America·Per LjungmanMichael Boeckh
Feb 13, 2009·BJOG : an International Journal of Obstetrics and Gynaecology·J M KoelewijnG J Bonsel
Jan 13, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Carolyn E BehrendtStephen J Forman
Aug 10, 2016·International Journal of Immunogenetics·A-M LittleD Sage
Feb 11, 2021·International Journal of Immunogenetics·Ann-Margaret LittlePaul A Wright
Jun 8, 2021·International Journal of Laboratory Hematology·Cigdem KekikFatma Savran Oguz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved